WallStreetZenWallStreetZen

NASDAQ: ARCT
Arcturus Therapeutics Holdings Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ARCT past revenue growth

How has ARCT's revenue growth performed historically?
Company
-19.03%
Industry
148.64%
Market
17.33%
ARCT's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ARCT's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ARCT's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ARCT earnings and revenue history

Current Revenue
$166.8M
Current Earnings
-$29.7M
Current Profit Margin
-17.8%

ARCT Return on Equity

Current Company
-10.1%
Current Industry
-63.5%
Current Market
188%
ARCT's Return on Equity (-10.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ARCT announces earnings.

ARCT Return on Assets

Current Company
-6.6%
Current Industry
2.9%
ARCT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ARCT Return on Capital Employed

Current Company
-12.8%
Current Industry
19.5%
ARCT has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ARCT vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ARCT$166.80M-$41.52M-$29.73M+60.31%N/A
PLRX$1.58M-$155.84M-$161.34M-59.21%N/A
CRGX$0.00-$92.85M-$98.15MN/AN/A
OCUL$58.44M-$66.42M-$80.74M+96.60%N/A
AUPH$175.51M-$63.05M-$78.02M+227.90%N/A
View Top Biotech Stocks

ARCT earnings dates

Next earnings date
May 7, 2024

Arcturus Therapeutics Holdings Earnings & Revenue FAQ

What were ARCT's earnings last quarter?

On Invalid Date, Arcturus Therapeutics Holdings (NASDAQ: ARCT) reported Q4 2023 earnings per share (EPS) of -$0.44, up 109.91% year over year. Total Arcturus Therapeutics Holdings earnings for the quarter were -$11.71 million. In the same quarter last year, Arcturus Therapeutics Holdings's earnings per share (EPS) was $4.44.

If you're new to stock investing, here's how to buy Arcturus Therapeutics Holdings stock.

What was ARCT's earnings growth in the past year?

As of Q2 2024, Arcturus Therapeutics Holdings's earnings has grown year over year. Arcturus Therapeutics Holdings's earnings in the past year totalled -$29.73 million.

What is ARCT's earnings date?

Arcturus Therapeutics Holdings's earnings date is Invalid Date. Add ARCT to your watchlist to be reminded of ARCT's next earnings announcement.

What was ARCT's revenue last quarter?

On Invalid Date, Arcturus Therapeutics Holdings (NASDAQ: ARCT) reported Q4 2023 revenue of $30.86 million up 80.75% year over year. In the same quarter last year, Arcturus Therapeutics Holdings's revenue was $160.29 million.

What was ARCT's revenue growth in the past year?

As of Q2 2024, Arcturus Therapeutics Holdings's revenue has grown -19.03% year over year. This is 167.67 percentage points lower than the US Biotechnology industry revenue growth rate of 148.64%. Arcturus Therapeutics Holdings's revenue in the past year totalled $166.80 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.